These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 8872421

  • 1. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E, Gianotti L, Ragusa L, Valetto MR, Cappa M, Aimaretti G, Ramunni J, Grottoli S, Camanni F, Ghigo E.
    Dementia; 1996; 7(5):288-92. PubMed ID: 8872421
    [Abstract] [Full Text] [Related]

  • 2. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 3. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 4. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F.
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [Abstract] [Full Text] [Related]

  • 5. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 6. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release.
    Friend K, Iranmanesh A, Login IS, Veldhuis JD.
    Eur J Endocrinol; 1997 Oct; 137(4):377-86. PubMed ID: 9368506
    [Abstract] [Full Text] [Related]

  • 7. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E.
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [Abstract] [Full Text] [Related]

  • 8. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 9. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ, Iglesias P, Selgas R, Bajo MA, Aguilera A.
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [Abstract] [Full Text] [Related]

  • 10. GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine.
    Beccaria L, Bosio L, Sanzari A, Aimaretti G, Ghigo E, Chiumello G.
    J Pediatr Endocrinol Metab; 1996 Nov; 9(6):577-83. PubMed ID: 9004172
    [Abstract] [Full Text] [Related]

  • 11. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [Abstract] [Full Text] [Related]

  • 12. Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine.
    Ghigo E, Nicolosi M, Arvat E, Marcone A, Danelon F, Mucci M, Franceschi M, Smirne S, Camanni F.
    Dementia; 1993 Sep; 4(6):315-20. PubMed ID: 8136894
    [Abstract] [Full Text] [Related]

  • 13. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 14. Effect of testosterone replacement therapy on the somatotrope responsiveness to GHRH alone or combined with pyridostigmine and on sympathoadrenal activity in patients with hypogonadism.
    Del Rio G, Carani C, Velardo A, Zizzo G, Procopio M, Coletta F, Marrama P, Ghigo E.
    J Endocrinol Invest; 1995 Oct; 18(9):690-5. PubMed ID: 8719299
    [Abstract] [Full Text] [Related]

  • 15. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
    [Abstract] [Full Text] [Related]

  • 16. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS, Scanlon MF, Peters JR.
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [Abstract] [Full Text] [Related]

  • 17. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.
    Giustina A, Bossoni S, Bodini C, Cimino A, Pizzocolo G, Schettino M, Wehrenberg WB.
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):510-7. PubMed ID: 1759540
    [Abstract] [Full Text] [Related]

  • 18. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.
    Ghigo E, Arvat E, Gianotti L, Nicolosi M, Valetto MR, Avagnina S, Bellitti D, Rolla M, Müller EE, Camanni F.
    Biol Psychiatry; 1994 Nov 15; 36(10):689-95. PubMed ID: 7880938
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone secretion in aging. Effect of pyridostigmine on growth hormone responsiveness to growth hormone-releasing hormone.
    Giusti M, Marini G, Sessarego P, Peluffo F, Valenti S, Caratti C, Giordano G.
    Recenti Prog Med; 1991 Dec 15; 82(12):665-8. PubMed ID: 1815302
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G, Grugni G, Morabito F.
    Minerva Endocrinol; 1998 Dec 15; 23(4):99-104. PubMed ID: 10361807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.